Protective effect of bacillus Calmette Guérin (BCG) vaccine in the prevention of leprosy: A meta-analysis

Indian Journal of Dermatology, Venereology and Leprology

Volumn 73, Issue 2, 2007, Pages 86-93

  Zodpey, Sanjay P ^a,b  

^a GOVERNMENT MEDICAL COLLEGE   (India)

^b NONE   (India)

Author keywords

BCG; Leprosy; Meta analysis; Protective effect

Indexed keywords

BCG VACCINE;

ARTICLE; BCG VACCINATION; CASE CONTROL STUDY; CHI SQUARE TEST; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; HUMAN; LEPROSY; MEDICAL LITERATURE; META ANALYSIS; PUBLICATION; RANDOMIZATION; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 34247608305     PISSN: 03786323     EISSN: None     Source Type: Journal    
DOI: 10.4103/0378-6323.31891     Document Type: Article

References (53)

1. Shepard CC. Vaccination against experimental infection with M. leprae. Am J Epidemiol 1965;81:150-63.
2. Convit J, Rassi E. Lepromin and tuberculin tests in Venezuelan leprosy foci: Induction of lepromin reaction by BCG vaccination. Int J Lepr 1954;22:303-10.
3. Doull JA, Guinto RS, Mabalay MC. Effect of BCG vaccination, lepromin testing and natural causes in inducing reactivity to lepromin and tuberculin. Int J Lepr 1957;25:13-37.
4. Tripathy SP. The case for BCG. Ann Natl Acad Med Sci 1983;19:11-21.
5. Randomized controlled trial of single BCG, repeated BCG or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Karonga Prevention Trial Group. Lancet 1996;348:17-24.
6. Ponnighaus JM, Fine PE, Sterne JA, Wilson RJ, Msosa E, Gruer PJ, et al. Efficacy of BCG vaccine against leprosy and tuberculosis in northern Malawi. Lancet 1992;339:636-9.
7. Sterne JA, Fine PE, Ponnighaus JM, Sibanda F, Munthali M, Glynn JR. Does bacille Calmette-Guérin scar size have implications for protection against tuberculosis or leprosy? Tuber Lung Dis 1996;77:117-23.
8. Orege PA, Fine PE, Lucas SB, Obura M, Okelo C, Okuku P. Case-control study of BCG vaccination as a risk factor for leprosy and tuberculosis in Western Kenya. Int J Lepr 1993;61:542-9.
9. Bagshawe A, Scott GC, Russell DA, Wingley SC, Merianos A, Berry G. BCG vaccination in leprosy: Final results of the trial in Karimui, Papua New Guinea, 1963-79. Bull WHO 1989;67:389-99.
10. DeSouza CN. Primary results of BCG in leprosy prophylaxis. Memoria del VI Congreso Internacional de Leprologia: Madrid; October 1953, p. 518-20 (In Spanish).
11. Fernandez JM. Influence of the tuberculosis factor on the clinical and immunological evolution of child contacts with leprosy patients. Int J Lepr 1955;23:243-58.
12. Convit J. Study on leprosy in the German ethnic group of Colonia Tovar, Venezuela. The morbidity rates in BCG vaccinated and unvaccinated groups during five years. Int J Lepr 1956;24:269-74.
13. Chatterjee KR, Soucou P, Sainte-Rose M. Prophylactic value of BCG vaccination against leprosy: A preliminary report. Bull Calcutta Sch Trop Med 1958;6:164-6.
14. Yanagisawa K. On the immunological relationship between tuberculosis and leprosy with special reference to the effect of BCG administration upon the prophylaxis of leprosy. La Lepro 1960;26-28:37-47.
15. Stanley SJ, Howland C, Stone MM, Sutherland I. BCG vaccination of children against leprosy in Uganda: Final results. J Hyg 1981;87:233-48.
16. Tripathy SP. BCG trial in leprosy. Indian J Lepr 1984;56:686-7.
17. Lwin K, Sudaresan T, Gyi MM, Bechelli LM, Tamondong C, Garbajosa PG, et al. BCG vaccination of children against leprosy: Fourteen - year findings of the trial in Burma. Bull WHO 1985;63:1069-78.
18. Scott GC, Russell DA, Boughton CR, Vincin DR. Untreated leprosy: probability for shifts in Ridley-Jopling classification. Development of "flares", or disappearance of clinically apparent disease. Int J Lepr 1976;44:110-22.
19. Chaudhury S, Hazra SK, Saha B, Mazumder B, Biswas PC, Chattopadhya D, et al. An eight-year field trial on anti leprosy vaccines among high-risk household contacts in the Calcutta Metropolis. Int J Lepr 1994;62:389-94.
20. Gupte MD. Field trials of antileprosy vaccines. Indian J Lepr 1998;70:363-7.
21. Gupte MD, Vallishayee RS, Anantharaman DS, Nagaraju B, Sreevatsa, Balasubramanyam S, et al. Comparative leprosy vaccine trial in South India. Indian J Lepr 1998;70:369-88.
22. Fine PE, Ponnighaus JM, Maine N, Clarkson JA, Bliss L. Protective efficacy of BCG against leprosy in Northern Malawi. Lancet 1986;2:499-502.
23. Abel L, Cua VV, Oberti J, Lap VD, Due LK, Grosset J, et al. Leprosy and BCG in Southern Vietnam (letter). Lancet 1990;335:1536.
24. Muliyil J, Nelson KE, Diamond EL. Effect of BCG on the risk of leprosy in an endemic area: A case-control study. Int J Lepr Other Mycobact Dis 1991;59:229-36.
25. Rodrigues ML, Silva SA, Neto JC, de Andrado AL, Mrtelli CM, Zicker F. Protective effect of intradermal BCG against leprosy: A case-control study in Central Brazil. Int J Lepr 1992;60:335-9.
26. Convit J, Sampson C, Zuniga M, Smith PG, Plata J, Silva J, et al. Immunoprophylactic trial with combined Mycobacterium leprae/BCG vaccine against leprosy: Preliminary results. Lancet 1992;339:446-50.
27. Convit J, Smith PG, Zuniga M, Sampson C, Ulrich M, Plata JA, et al. BCG vaccination protects against leprosy in Venezuela: A case-control study. Int J Lepr Other Mycobact Dis 1993;61:185-91.
28. Barker DM, Nguyen-van-Tam JS, Smith SJ. Protective efficacy of BCG vaccine against leprosy in southern Malawi. Epidemiol Infect 1993;111:21-5.
29. Thuc NV, Abel L, Lap VD, Oberti J, Lagrange PH. Protective effect of BCG against leprosy and its sub-types: A case-control study in Southern Vietnam. Int J Lepr 1994;62:532-8.
30. Boelens JJ, Kroes R, Beers SV, Lever P. Protective effect of BCG against leprosy in South Sulawesi, Indonesia. Int J Lepr Other Mycobact Dis 1995;63:456-7.
31. Lombardi C, Pedrazzani ES, Pedrazzani JC, Filho PF, Zicker F. Protective efficacy of BCG against leprosy in Sao Paulo. Bull Pan Am Health Organ 1996;30:24-30.
32. Bertolli J, Pangi C, Frerichs R, Halloran ME. A case-control study of the effectiveness of BCG vaccine for preventing leprosy in Yangon, Myanmar. Int J Epidemiol 1997;26:888-96.
33. Zodpey SP, Shrikhande SN, Salodkar AD, Maldhure BR, Kulkarni SW. Effectiveness of Bacillus Calmette-Guérin (BCG) vaccination in the prevention of leprosy: A case-control study in Nagpur, India. Int J Lepr Other Mycobact Dis 1998;66:309-15.
34. Zodpey SP, Bansod BS, Shrikhande SN, Maldhure BR, Kulkarni SW. Protective effect of Bacillus Calmette-Guérin (BCG) against leprosy: A population based case-control study in Nagpur, India. Lepr Rev 1999;70:287-94.
35. Mohyuddin G. BCG vaccination and leprosy. Indian J Lepr 1992;64:545-6.
36. Lau J. Meta-analyst version 0.99x. New England Medical Center: Boston, MA; 1998.
37. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
38. Prakash O. Antileprosy vaccine: An apprehension. Int J Lepr Other Mycobact Dis 1995;63:572-3.
39. Fine PE. Primary prevention of leprosy. Int J Lepr Other Mycobact Dis 1996;64:S44-9.
40. Fernandez JM. The early reaction induced by lepromin. Int J Lepr Other Mycobact Dis 1940;8:1-14.
41. Springett VH, Sutherland I. Comparison of the efficacy of liquid and freeze-dried strains of BCG vaccine in preventing tuberculosis. Br Med J 1970;4:148-50.
42. st ed. M/s Banarsidas Bhanot Publishers: Jabalpur; 2006. p. 6-140.
43. Fine PE, Rodrigues LC. Modern vaccines: Mycobacterial diseases. Lancet 1990;335:1016-20.
44. Britton WJ. Immunoprophylaxis against leprosy: The case for improved vaccines against leprosy. Int J Lepr Other Mycobact Dis 1996;64:S77-9.
45. Fine PE. Reflections on the elimination of leprosy. Int J Lepr 1992;60:71-80.
46. Fine PE. Leprosy- the epidemiology of a slow bacterium. Epidemiol Rev 1982;4:161-88.
47. Fine PE. The BCG story: Lessons from the past, implications for the future. Rev Infect Dis 1989;11:S353-9.
48. Ponnighaus JM, Fine PE, Sterne JA, Bliss L, Wilson RJ, Malema SS, et al. Incidence rates of leprosy in Karonga District, Northern Malawi: Patterns by age, sex, BCG status and classification. Int J Lepr Other Mycobact Dis 1994;62:10-23.
49. Trial of BCG vaccines in South India for tuberculosis prevention. Indian J Med Res 1979;70:349-63.
50. Trial of BCG vaccines in south India for tuberculosis prevention: First report - Tuberculosis Prevention Trial. Bul World Health Organ 1979;57:819-27.
51. Tuberculosis Prevention Trial, Madras. Indian J Med Res 1980;72:1-74.
52. Fifteen year follow up of trial of BCG vaccines in south India for tuberculosis prevention. Tuberculosis Research Centre (ICMR), Chennai. Indian J Med Res 1999;110:56-69.
53. Fine PE. Variation in protection by BCG: Implications of and for heterologous immunity. Lancet 1995;346:1339-45.